Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]

mCRPC: Latest developments in diagnostics and combination therapies

Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor

mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally...

Dr Terence Friedlander - UCSF, San Francisco, USA

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for...

Dr Ian Chau - The Royal Marsden, London, UK

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC ( Dr Ian Chau - The Royal Marsden, London, UK )

Olaparib improves disease-free survival in high-risk early-stage HER2-negative...

Prof Andrew Tutt - Institute of Cancer Research, London, UK

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first...

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

UpSwinG: Real-world, non-interventional cohort study on TKI activity in...

Dr Satoru Miura - Niigata Cancer Center Hospital, Niigata, Japan

UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients with EGFRm NSCLC with uncommon mutations ( Dr Satoru Miura - Niigata Cancer Center Hospital, Niigata, Japan )

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small...

Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer ( Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France )

Efficacy and early discontinuation predictors in NSCLC patients receiving...

Dr Giulia Pasello - University of Padova, Padua, Italy

Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab ( Dr Giulia Pasello - University of Padova, Padua, Italy )

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA...

Dr Matthew Marx - Mirati Therapeutics, San Diego, USA

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )

Palliative Care: Industry and Academia – Tensions and Opportunities

Dr Jim Cleary - IU Simon Cancer Center, Indianapolis, USA

Palliative Care: Industry and Academia – Tensions and Opportunities ( Dr Jim Cleary - IU Simon Cancer Center, Indianapolis, USA )

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and...

Dr Martina Lorenzi - University of Padua, Padua, Italy

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world ( Dr Martina Lorenzi - University of Padua, Padua, Italy )

More from ecancer